Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158079 · ClinicalTrials.gov registry record · Phase 1
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01158079 is a Phase 1 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT01158079, a Phase 1 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.
Interventions
- DRUG ALN-VSP02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158079
The ClinicalTrials.gov registry entry for NCT01158079 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALN-VSP02 is the first listed.
NCT01158079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158079 about?
NCT01158079 is a clinical study titled "Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment". This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.
What is the current status of trial NCT01158079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01158079?
The interventions under investigation include: ALN-VSP02 (DRUG).
Who is sponsoring clinical trial NCT01158079?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.